Education
About Us
Working with TipRanks
Follow Us
Alpha Tau Medical Ltd (DRTS)
NASDAQ:DRTS
DRTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.75 - $4.39
Previous CloseN/A
Volume116.73K
Average Volume (3M)49.71K
Market Cap
$245.63M
Enterprise Value$201.40M
Total Cash (Recent Filing)$71.03M
Total Debt (Recent Filing)$12.56M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Aug 21, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding84,699,720
10 Day Avg. Volume44,301
30 Day Avg. Volume49,714
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)1.91
Price to Sales (P/S)0.00
P/FCF Ratio-8.15
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-187.52
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$7.00Price Target Upside141.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Alpha Tau Medical Ltd News
PremiumCompany Announcements
Alpha Tau Medical Ltd. Approves Key Proposals at Annual Meeting
PremiumCompany Announcements
Alpha Tau Medical to Present at Jefferies Healthcare Conference
PremiumCompany Announcements
Alpha Tau Medical Reports Promising Q1 2025 Results
PremiumCompany Announcements
Alpha Tau Medical Reports Q1 2025 Results and Major Clinical Advances
PremiumCompany Announcements
Alpha Tau Medical Schedules Annual Shareholder Meeting for June 2025Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company received an IDE from the FDA to conduct a U.S. pilot study of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM).
Facility ExpansionThe Hudson, NH facility is slated to complete its first phase of construction and come online for production of Alpha DaRT, indicating progress in manufacturing capabilities.
Strategic InvestmentA $36.9M strategic investment from Oramed validates Alpha Tau’s novel technology and its potential in oncology therapeutics.
Bears Say
Clinical Trial RisksFailure of Alpha DaRT in clinical trials poses a significant risk to the company's future success.
Commercial Success RisksFailure to achieve commercial success is a notable risk for the company's future financial performance.
Regulatory Approval RisksRisks include failure of Alpha DaRT in clinical trials, failure to secure regulatory approval in the U.S., failure to achieve commercial success, and potential dilution risk.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.04% Mutual Funds
0.69% Other Institutional Investors
99.27% Public Companies and
Individual Investors
DRTS FAQ
What was Alpha Tau Medical Ltd’s price range in the past 12 months?
Alpha Tau Medical Ltd lowest stock price was $1.75 and its highest was $4.39 in the past 12 months.
What is Alpha Tau Medical Ltd’s market cap?
Alpha Tau Medical Ltd’s market cap is $245.63M.
When is Alpha Tau Medical Ltd’s upcoming earnings report date?
Alpha Tau Medical Ltd’s upcoming earnings report date is Aug 21, 2025 which is in 59 days.
How were Alpha Tau Medical Ltd’s earnings last quarter?
Alpha Tau Medical Ltd released its earnings results on May 19, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.123 by $0.003.
Is Alpha Tau Medical Ltd overvalued?
According to Wall Street analysts Alpha Tau Medical Ltd’s price is currently Undervalued.
Does Alpha Tau Medical Ltd pay dividends?
Alpha Tau Medical Ltd does not currently pay dividends.
What is Alpha Tau Medical Ltd’s EPS estimate?
Alpha Tau Medical Ltd’s EPS estimate is -0.12.
How many shares outstanding does Alpha Tau Medical Ltd have?
Alpha Tau Medical Ltd has 84,699,720 shares outstanding.
What happened to Alpha Tau Medical Ltd’s price movement after its last earnings report?
Alpha Tau Medical Ltd reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.123. Following the earnings report the stock price went up 5.161%.
Which hedge fund is a major shareholder of Alpha Tau Medical Ltd?
Currently, no hedge funds are holding shares in DRTS
Alpha Tau Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (141.38% Upside)
$7.00 (141.38% Upside)
Hedge Fund Trend
Decreased
By 60.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ―
Last 30 Days ―
Last 30 Days ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.31%
12-Months-Change
Fundamentals
Return on Equity
-47.95%
Trailing 12-Months
Asset Growth
-21.00%
Trailing 12-Months
Company Description
Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
DRTS Stock 12 Month Forecast
Average Price Target
$7.00
▲(141.38%Upside)
Technical Analysis
Annexon Biosciences
―
Foghorn Therapeutics
―
Inhibikase Therapeutics
―
Nanobiotix
―
Prime Medicine, Inc.
―